Potential of minimally invasive procedures in the treatment of uterine fibroids: a focus on magnetic resonance-guided focused ultrasound therapy

Krisztina Fischer1–3
Nathan J McDannold1
Clare M Tempany1
Ferenc A Jolesz1,†
Fiona M Fennessy1,4

1Department of Radiology, 2Renal Division, 3Biomedical Engineering Division, Brigham and Women’s Hospital, 4Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

†Ferenc A Jolesz passed away on December 31, 2014

Abstract: Minimally invasive treatment options are an important part of the uterine fibroid-treatment arsenal, especially among younger patients and in those who plan future pregnancies. This article provides an overview of the currently available minimally invasive therapy options, with a special emphasis on a completely noninvasive option: magnetic resonance-guided focused ultrasound (MRgFUS). In this review, we describe the background of MRgFUS, the patient-selection criteria for MRgFUS, and how the procedure is performed. We summarize the published clinical trial results, and review the literature on pregnancy post-MRgFUS and on the cost-effectiveness of MRgFUS.

Keywords: uterine fibroids, MRgFUS, focused ultrasound, minimally invasive treatment

Introduction

In women of reproductive age, uterine fibroids (leiomyomas or myomas) are the most common single indication for hysterectomy,1 and account for significant health care costs.2 Current medical treatment options of uterine fibroids range from medical management (gonadotropin-releasing hormone [GnRH] therapy) to myomectomy, or to complete hysterectomy.3–5 The noninvasive option of magnetic resonance-guided focused ultrasound (MRgFUS) is becoming increasingly accepted, with over 9,880 patients treated to date worldwide with one system (ExAblate 2100, InSightec, Tirat Carmel, Israel). This treatment option is important in light of the fact that women are increasingly seeking less invasive alternatives to a classic surgical intervention and seeking procedures that offer shorter recovery times with the possibility of fertility preservation.6,7 Another important driving force in the development and widespread application of less invasive fibroid therapy is the reduction in treatment-associated health care cost.8,9 The purpose of this article is to summarize the literature to date on MRgFUS as a promising option for uterine fibroid treatment.

Uterine fibroids

The estimated incidence of uterine fibroids is approximately 70% in Caucasian females over 50 years of age, and is over 80% in African American females.2,10,11 While some patients are completely asymptomatic, approximately 25% are symptomatic and experience pelvic pain and/or pressure, menorrhagia or dysmenorrhagia, increased frequency of urination, or reproductive dysfunction.12,13 Fibroids are classified by their location in the uterus as subserosal, intramural, or submucosal. They can be pedunculated from either the serosal surface or from the mucosal surface.
Histologically, uterine fibroids are benign, hormone-sensitive smooth-muscle tumors mixed with fibrous connective tissue, demarcated from the surrounding tissue by a pseudocapsule. Fibroids can undergo hyaline degeneration or hemorrhagic infarction, and they may calcify as they regress after menopause. The goal of fibroid treatment is relief of symptoms, such as bleeding, pelvic pressure, or pain.6,13 Historically, the first-line treatment of uterine fibroids has been surgical intervention (hysterectomy or myomectomy). For women who desire fertility preservation, myomectomy has been a preferable option. Less invasive treatment options are available, such as uterine artery embolization (UAE), MRgFUS, or less common thermal ablation therapies using laser, radiofrequency, and cryoablation.6,14 Medical therapy using hormone-based treatment is also available,15 but may have a rebound effect once discontinued.16 Hormone therapy is often used in patients who present with heavy menstruation or as a presurgical adjunct for those with large fibroids, as they reduce the endometrial hyperplasia associated with the fibroid (progestogens) and induce the shrinkage of the fibroid (GnRH-antagonist effect).16

**Surgical therapeutic options – hysterectomy and myomectomy**

For perimenopausal women with symptomatic fibroids who are family-complete, hysterectomy (the surgical removal of the uterus) is an effective treatment. Uterine fibroids remain the most common indication for hysterectomy in the US.6,14 However, hysterectomy is a major operation, and can cause significant disability for 2 months postoperatively.17,18 The mortality rate is 0.38–1 per 1,000 patients, significant complications develop in 3% of patients, and minor complications are experienced by up to 30% of patients.17–19 The long-term consequences of hysterectomy may include urinary incontinence and early ovarian failure,20,21 in addition to the potential psychological consequences of the uterus removal.22 There is an increased trend of women desiring pregnancies later in their reproductive age, and as such there is an increased demand for conservative treatment of fibroids. An alternative to hysterectomy is an open or laparoscopic myomectomy. Open myomectomy results in high patient satisfaction, and approximately 80% of patients report alleviation in their symptoms;23 however, recovery can take 6–8 weeks.24,25 Patients who undergo open myomectomy are usually younger, weigh less, are of lower parity, and have smaller fibroids and uterus size compared to patients who undergo hysterectomy.23 The most common side effects are fever and hemorrhage in both procedures.19

When pregnancy is desired and the uterus is small (<5 cm) with a small number (fewer than three) of fibroids, laparoscopic myomectomy can be considered.1,26 Smaller fibroids (3–8 cm) can be removed from the uterus via a laparoscopic approach (for intramural and subserosal fibroids) or a hysteroscopic approach (for submucosal fibroids). Several studies have shown that laparoscopic myomectomy is associated with shorter hospital stay, less postoperative pain, and reduced blood loss compared to hysterectomy and open myomectomy.27–30 Removal of larger fibroids in this fashion is more difficult, and a common surgical strategy has been the use of morcellation. However, of recent times, the US Food and Drug Administration (FDA) has recommended against the use of this technique.31,32 As indicated on the FDA website, [the] FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids. The procedure poses the risk of spreading undetected cancerous tissue in women with unsuspected cancer.

If morcellation is banned, a new management strategy for larger uterine fibroids may have to be considered.31,32

Small (<5 cm) submucosal fibroids may be accessible by hysteroscopic removal. After cervical dilatation, the hysteroscope is inserted transvaginally into the uterine cavity, the cavity is insufflated, and after careful inspection, the fibroid can be removed.33

**Minimally invasive nonsurgical therapies**

**Uterine artery embolization**

UAE was introduced in 1995, and is widely used and accepted for the treatment of uterine fibroids.34–36 Absolute contraindications to the procedure are pregnancy, active infection, or suspected malignancy (uterine, cervical, or adnexal). Relative contraindications are coagulopathy, severe contrast allergy, or renal impairment.37 The procedure involves catheterization of a femoral artery, through which the uterine artery is accessed. Embolization is brought about through bilateral intra-arterial infusion of microparticles, producing blockage in the arterial blood flow to the uterus. UAE treatment efficacy is high, the patients’ symptoms improve in 80%–90% of cases, and the median duration of hospital stay and recovery times are shorter compared with hysterectomy.38,39 The major complication rate is low (1%–4%).17,19,39 The rate of hysterectomy for major complications postprocedure is 1.1%–1.5%.17,40 Other complications of UAE are postprocedural pain, ovarian failure, and allergic reaction to the injected compound.41–45 Over time, the
rate of complications after UAE has been decreasing, with greater operation experience and technical advancement. The overall failure and recurrence rate in patients who were enrolled in the Fibroid registry, which looked at long-term outcomes after UAE, was 20% at 5 years.

Image-guided thermal therapies
Thermal ablation occurs when there is a rapid change in the local tissue temperature (>55°C for heat and <−20°C to −50°C for cold) in response to the targeted therapy. Imaging is critically important in thermal ablation. It provides information on tumor detection, characterization, and guidance for treatment targeting. Currently, MR imaging (MRI) is the only modality that is able to provide such information and guidance, including reliable real-time quantitative temperature measurements. Current minimally invasive thermal ablation techniques include laser, cryo-, and radiofrequency ablation (RFA).

Laser ablation of uterine fibroids
Laser ablation of the fibroids can be performed through a laparoscopic or endoscopic route (since 1989), or as a percutaneous (since 1999) treatment with the assistance of MRI guidance. The treatment uses interstitial laser photocoagulation, which applies a low-power laser to destroy the fibroid tissue, guided by thermal monitoring. It uses a 1,064 nm-wavelength laser that penetrates deep into tissue. Laparoscopic or hysteroscopic laser ablation has been shown to decrease fibroid volume by 50%–70%.

Cryotherapy
Cryoablation is an ablation technique that damages tissues by rapid freezing and rapid thawing using high-pressure argon gas (temperature −20°C to −50°C). The temperature change leads to vascular stasis, thrombosis, and ultimately local tissue ischemia. As a result, the cell membranes rupture and the cells die. Cryoablation of the fibroid can take place through a laparoscopic or hysteroscopic approach. Since the early 2000s, it has been performed with MRI guidance. The reduction of the mean fibroid size ranges between 31% and 80%. The postprocedural complications can include fever and infection.

Radiofrequency ablation
RFA was first used for fibroid treatment in 2005 through a laparoscopic approach. Ultrasound or CT (computerized tomography) scan is used to guide the procedure. Since RFA is incompatible with MRI, there is no reliable way to monitor the local temperature or to estimate the true ablation area. The advantage of RFA over cryoablation is that a larger ablation area (up to 6 cm in diameter) can be achieved in a reasonable time (~30 minutes). No major complications are associated with RFA; in some cases, spotting bleeding can last up to 8 weeks postablation.

Noninvasive therapeutic option for uterine fibroid treatment: magnetic resonance-guided focused ultrasound surgery
Milestones in the development of MRgFUS
Wood and Loomis, who are often called the “fathers of ultrasonics”, were the first to describe that US has a biologic effect on living tissues in the 1920s. In 1942, Lynn et al proposed the use of FUS to induce thermal or mechanical effects at a focal location in living tissue. Subsequently, the Fry brothers built a clinical FUS device to treat hyperkinetic diseases, such as Parkinson’s disease in the 1950s. In the 1980s, FUS was introduced as a treatment option for glaucoma, and the FDA approved the first FUS system (Sonocare CST-100) to treat glaucoma shortly thereafter. Hynnen et al and others introduced MRgFUS in the 1990s. It contained a single geometrically focused transducer adopted to perform in a high-field-strength MR magnet. In the 2000s, the first MRI-compatible phased array and its driving system were introduced to create a larger treated volume of tissue, and to deliver sonication in different locations by steering the US beam from one target to the next. In the same time period, MRI-based thermal dosimetry was developed for guidance and for confirmation of thermal delivery.

In 2004, the ExAblate 2000 system (InSightec) received FDA clearance for fibroid treatments. Currently, there are two FDA-approved MRgFUS platforms: the ExAblate 2000 and the ExAblate 2100 (InSightec). Sonalleve MR-HIFU (Philips Healthcare, Andover, MA, USA) is another system approved in Europe. Since its introduction to the market in 2004, the ExAblate systems have treated 9,880 patients to date (10,527 uterine fibroids; information provided by InSightec). MRgFUS has also been used as a palliative treatment of bone metastases, breast fibroadenomas, breast cancer, brain tumors, and liver disease.

Patient selection for MRgFUS
One of the first steps in selecting patients for MRgFUS treatment is to determine symptomatology and confirm the presence of uterine fibroids, as other conditions (such as adenomyosis) can cause similar symptomatology.
At our institution, all suitable candidates complete the symptom-severity score (SSS) of the Uterine Fibroid Symptoms and Quality of Life (UFS-QOL) questionnaire, a validated instrument for assessing symptoms specific for quality of life due to uterine fibroids. The SSS of the UFS-QOL is a 100-point scale composed of eight questions, assessing symptoms related to bleeding and bulk- or volume-related complaints. The score is significantly higher in women with symptomatic fibroids. This objective scoring system is used for preprocedure evaluation and postprocedure monitoring.

All eligible candidates undergo a contrast-enhanced MRI to determine fibroid signal intensity, size, number, and location (Table 1). The optimal scenario for MRgFUS treatment is a solitary fibroid ≤10 cm in diameter, of low signal intensity on T2-weighted images on MRI, enhances on contrast images, and is accessible by the MRgFUS system (ie, <12 cm from margin of the skin; ExAblate 2000/2100) (Figure 1). Therefore, fibroids that do not demonstrate adequate enhancement or have areas of peripheral calcification (Figure 2) may not be good candidates. Fibroids that are too small and multiple in number (Figure 3) and without a dominant candidate for targeting are not suitable for MRgFUS either. As multiple sonications are needed to destroy the desired fibroid volume, treatment volume is limited by the treatment time that is realistically feasible for the patient. The total treatment time for a 7–8 cm fibroid (depending on energy absorption and location) is ~3 hours of MRgFUS ablation. Larger fibroids may require significantly longer treatment. In addition, fibroids that are of high signal intensity on T2-weighted images (Figure 4) may indicate cellular fibroids, which can be difficult to obtain an optimal temperature increase in. It is possible that pretreatment with a GnRH agonist may help “dry out” these fibroids ahead of time, allowing for higher-temperature deposition at treatment.

For larger fibroids, pretreatment with GnRH agonists may allow for fibroid shrinkage, which can result in shortened treatment times. Overall, by reducing vascularity, energy deposition can be potentiated. Therefore, GnRH-agonist treatment prior to MRgFUS will increase efficacy. On the other hand, the absence of enhancement in contrast imaging may indicate nonperfused and necrotic tissue, in which case the patient may not benefit from the MRgFUS treatment. While fibroid number and size are important to consider, so also is fibroid location. If pedunculated and subserosal, there is a risk of amputation of the fibroid from the uterus.

There are physical limitations of each MRgFUS system. For example, the ExAblate system allows sonications to be delivered up to 12 cm vertical distance from the skin of the anterior abdominal wall. As the goal of treatment is to target as much of the fibroid as possible (up to 100%), fibroids where not all tissue is accessible may not have as good an

### Table 1 MR imaging findings that require evaluation on the screening MR and on the planning MR on treatment day

<table>
<thead>
<tr>
<th>Finding</th>
<th>Possible limitation</th>
<th>Possible remediation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>Too small</td>
<td>Poor treatment effect</td>
</tr>
<tr>
<td></td>
<td>Too large (&gt;10 cm)</td>
<td>Poor treatment effect</td>
</tr>
<tr>
<td>Location</td>
<td>Too posterior (&gt;12 cm from the center of the fibroid to abdominal wall)</td>
<td>Limited beam penetration</td>
</tr>
<tr>
<td></td>
<td>&lt;4 cm to sacrum</td>
<td>Heating of sacrum and causing sciatic nerve injury</td>
</tr>
<tr>
<td>Submucosal or subserosal (especially pedunculated)</td>
<td>Risk of expulsion</td>
<td>Consider endoscopic treatment</td>
</tr>
<tr>
<td>Fibroid character</td>
<td>Degenerated (nonperfusion)</td>
<td>Poor treatment effect</td>
</tr>
<tr>
<td></td>
<td>Calcification</td>
<td>Reflection of beam/possible deposition of heat proximal to calcification</td>
</tr>
<tr>
<td></td>
<td>Hypercellular (high signal on T2WI)</td>
<td>Difficulty in heat deposition</td>
</tr>
<tr>
<td>Acoustic window</td>
<td>Abdominal scar</td>
<td>May deviate ultrasound wave/skin burn</td>
</tr>
<tr>
<td></td>
<td>Intervening visceral organ (bladder or bowel)</td>
<td>Visceral organ damage</td>
</tr>
</tbody>
</table>

**Abbreviations:** GnRH, gonadotropin-releasing hormone; MRgFUS, magnetic resonance-guided focused ultrasound; T2WI, T2-weighted image.
outcome. Also, if the fibroid is too close to the sacrum, the heating of the sacral bone may lead to sciatic nerve injury. Therefore, fibroids that are close to the lumbosacral plexus or to bone surfaces should only be considered suitable for MRgFUS if there is at least 4 cm distance between the fibroid and the bone surface.

Treatment procedure

Preparation for the procedure

After fasting overnight, the patient arrives at the outpatient MRI suite. The patient’s abdomen has to be clean of any type of lotion or cream, as even small amount of these products can cause skin burn during treatment. The abdomen is shaved between the umbilicus and 1 cm below the pubic bone, a urinary catheter is placed into the bladder, and an intravenous line is sited for administration of conscious sedation.

Treatment planning

The MRgFUS is planned and performed with the patient in a prone position (Figure 5). The patient lies on a custom-built patient-scanner table, which houses all of the electronics and the phased array transducer in a sealed water bath. This table docks to the magnet. To ensure good acoustic coupling with the patient’s abdomen, a gel pad is placed between the transducer and the patient’s skin. A mixture of degassed water and US gel is applied to both sides of the gel pad to avoid air bubbles. Multiplanar T2-weighted images are taken of the pelvis, and are transferred to the ExAblate/Sonalleve planning program. The region of treatment is manually drawn and defined within the capsule of the fibroid. The target volume is analyzed with superimposed US-beam paths in all three planes. By angling the beam path, the target can be optimally accessed and unwanted heating can be avoided. When bowel...

Figure 1 Sagittal MRI of a typical case pre/post treatment.

Notes: (A) Sagittal T2-weighted image (T2WI) demonstrating a single uterine fibroid of predominantly low signal intensity, accessible by the ultrasound transducer, which is imbedded in the magnetic resonance table. (B) Sagittal T1-weighted image (T1WI) postcontrast at screening demonstrates heterogeneous enhancement of the fibroid. (C) Sagittal T1WI postadministration of intravenous contrast after MRgFUS treatment demonstrates lack of enhancement in the fibroid, consistent with treatment effect.

Abbreviations: MRgFUS, magnetic resonance-guided focused ultrasound; MRI, magnetic resonance image.

Figure 2 Examples of MRgFUS screen failures.

Notes: (A) Sagittal T1-weighted image (T1WI) prior to contrast demonstrates area of very low signal along the inferior margin of the fibroid. (B) After administration of contrast agent, there is lack of enhancement in the majority of the fibroid, and the clumpy areas of low signal are again seen. Both of these factors — lack of enhancement and clumpy low signal areas consistent with peripheral calcifications — are reasons for screen failure for an MRgFUS treatment. (C) Sagittal T1WI postadministration of intravenous contrast in a different case demonstrating complete lack of enhancement in two uterine fibroids; this case was also a screen failure.

Abbreviation: MRgFUS, magnetic resonance-guided focused ultrasound.
loops are found beneath the abdominal wall, they can usually be moved out of the beam path by distending the bladder with saline or using large gel pads on the abdomen wall to apply external pressure.\textsuperscript{75,81}

**Procedure**

Just prior to the procedure being started, titrated doses of fentanyl and midazolam are administered intravenously to alleviate anxiety and relieve pain. The patient, however, should remain conscious, responsive, and able to give feedback throughout the procedure. The MRgFUS procedure starts with low-power sonications (50–100 W). Real-time thermometry is performed through the proton-resonance frequency-shift method.\textsuperscript{66,69} Sonication location is determined, and the targeting accuracy can be confirmed. If the targeting is accurate, additional sonications are delivered at therapeutic power level to confirm the appropriate thermometry. The goal of the treatment is to increase the local temperature in the selected tissue volume over 60°C, which ensures coagulative necrosis in the tissue.\textsuperscript{81,82} Between each sonication, adequate cooling time is ensured to avoid thermal buildup and damage to normal tissues: the ExAblate 2100 and the Sonalleve systems do this calculation automatically, and they apply subsequent sonications in a relatively distant place to allow adequate cooling time for the tissue. The procedure continues with delivery of all planned sonications. During the treatment, to ensure no complications occur, continuous communication with the patient is very important.

At the end of the MRgFUS treatment, we assess the treatment effect by measuring the nonperfused volume (NPV) of fibroid tissue on gadolinium contrast-enhanced T1-weighted images. Higher NPV ratios are associated with lower probabilities of recurrence, due to fibroid regrowth and a reduced need for additional procedures.\textsuperscript{76–78,83}

---

**Figure 3** Example of MRgFUS screen failure due to innumerable small fibroids.

Notes: (A) Axial, (B) coronal, and (C) sagittal T2-weighted image of a patient with innumerable, small uterine fibroids, without a definite dominant fibroid. Cases such as these are not good candidates for MRgFUS.

**Abbreviation:** MRgFUS, magnetic resonance-guided focused ultrasound.

**Figure 4** Illustrative example of cellular fibroid.

Notes: (A) Axial, (B) coronal, and (C) sagittal T2-weighted image (T2WI) demonstrating a fibroid of high signal intensity on T2WI. These fibroids are thought to represent very cellular fibroids, and may be difficult to treat.
Obstacles in the FUS-beam path

US energy is absorbed to a greater extent by high-density tissues as abdominal wall scar tissue, and is reflected by low-density tissues (eg, containing air), such as the intestines or the air-containing catheter in the bladder.\(^{84,85}\) In some cases, the angulation (tilting the beam path away) of the US-beam path can help to avoid these tissues. Alternatively, the bladder can be filled with saline to enable the beam to pass through the bladder. The presence of bowel loops behind the anterior abdominal wall and in front of the uterus fibroids can sometimes be manipulated by filling the bladder with saline and filling the rectum with US gel, and displacing the bowel loops to create a sonication window (Figure 6).

Clinical trial results

The initial Phase I/II trial of the ExAblate 2000 device was conducted to evaluate the safety and feasibility of MRgFUS.\(^{86}\) In this trial, premenopausal women with symptomatic fibroids, defined by their SSS from the UFS-QOL questionnaire, were recruited. Treatment was limited to 100 mL of fibroid tissue, a 15 mm safety margin from both the serosal surface and the endometrium of the uterus, and 2 hours of sonication. In this trial, all patients went to a planned hysterectomy within 1 month, allowing for direct pathological correlations. It was demonstrated that MRgFUS could successfully cause thermal coagulation and necrosis in uterine fibroids.

Subsequently, a multicenter Phase III clinical trial was carried out to evaluate the effectiveness and durability of the treatment.\(^{82,87,88}\) In this trial, patients did not receive any additional forms of therapy after MRgFUS. Enrollment criteria included symptomatic fibroids in patients who had no desire for further pregnancy. The patients were followed, and the outcome was documented using the UFS-QOL questionnaire scores at 6, 12, and now 24 months after treatment, and by fibroid volume on MRI. In 2004, after receiving FDA clearance, the treatment guidelines were changed to allow a

Figure 5 Photograph depicting a patient lying in the prone position on the magnetic resonance (MR) table. Notes: The focused ultrasound transducer array is located within the MR table, and the patient is positioned such that the fibroid overlies the ultrasound transducer. Reprinted with permission from InSightec Inc.

Figure 6 Illustrative example of manipulation of beam path obstruction. Notes: (A) Screening sagittal T2-weighted image (T2WI) and (B) axial T2WI of an accessible solitary uterine fibroid, which demonstrated enhancement postadministration of intravenous contrast agent on sagittal and axial T1 postcontrast images (C, D). However, on the day of treatment, sagittal localizing images demonstrated multiple bowel loops anterior to the uterus (E). The bowel loops were manipulated by filling the bladder with saline and filling the rectum with ultrasound gel (F, sagittal localizer), which displaced the bowel loops superiorly to create a sonication window. After the bladder was emptied, the sonication window remained (G, sagittal localizer), allowing for satisfactory treatment (H, sagittal T1-weighted image (T1WI) postadministration of contrast agent) with a large area of nonenhancement.
treatment volume of 150 mL per fibroid, with no restriction on the distance from the endometrium. Fennessy et al\textsuperscript{82} first analyzed the effect of the different protocols on treatment results, and found that the relaxed treatment protocol resulted in a greater NPV, with 25.79\% achieved versus the 16.65\% of the restricted protocol ($P<0.001$).\textsuperscript{82} For those treated with the restricted protocol, clinical follow-up revealed that 74\% of patients at 6 months and 73\% at 12 months had a greater than 10-point improvement in symptom score. In those treated according to the more relaxed protocol, 88\% reported a 10-point or greater symptom improvement at 6 months, and 91\% had significant symptom improvement at 12 months. This study was the first to show that treating a greater amount of fibroid tissue resulted in a larger treatment volume and better symptom improvement and durability.

This need for increased NPVs and better outcomes has been replicated in multiple papers since then.\textsuperscript{77,83,89-91} In all, these papers underscore that the learning process and the worldwide accumulation of data on MRgFUS of uterine fibroids has led to treatment optimization to safely achieve large-enough NPVs that will ensure sustained clinical benefit.

**MRgFUS as a treatment option for African–American women**

Uterine fibroids have a disproportionate impact on African–American (AA) women. They have an earlier age of onset with more symptomatic fibroids than non-AA women,\textsuperscript{92-94} with different effects on employment and therapy-seeking behavior.\textsuperscript{95} A recent study by our group found that AA women tended to have differences in the pattern of fibroid disease, with a higher total number of fibroids that were of smaller volume, compared to non-AA women (Figure 3).\textsuperscript{96} Specific to MRgFUS, AA patients were more likely to fail screening than non-AA patients, ie, they were more likely to be unsuitable candidates for MRgFUS. This was more likely to be due to MRI findings that indicated that safe delivery of treatment was not possible, such as significant anterior abdominal wall scarring or multiple small fibroids. However, once AA patients pass screening and were treated with MRgFUS, the two groups do not differ in terms of their need for surgical intervention for failed MRgFUS treatment and in terms of their overall symptom improvement and fibroid shrinkage.

**MRgFUS and fertility and pregnancy**

Early clinical trials and initial treatment protocols of MRgFUS included only women who were family-complete.\textsuperscript{87,88} In recent years, there have been several case reports of successful pregnancies following MRgFUS treatment,\textsuperscript{97-104} which are summarized in a recent review article by Clark et al.\textsuperscript{105} As MRgFUS does not target the uterus, it remains intact, and anecdotal pregnancies are to be expected. Rabinovici et al published the largest case study results of 54 pregnancies in 51 patients who received MRgFUS on average 8 months before conception.\textsuperscript{99} The term-delivery rate was reported to be 93\%, and the C-section rate was remarkably lower than that seen after UAE.\textsuperscript{106-108} In addition, it is notable that in this series, there were neither low-birth-weight infants nor stillbirths, which have been reported (albeit at a low frequency) in women who become pregnant post-UAE. While women who conceive after MRgFUS should be informed that normal pregnancy outcomes and normal vaginal deliveries are possible, since our knowledge is currently limited, these pregnancies need to be followed up carefully.

**Technical improvements**

In recent years, different approaches have been developed to increase the treatment volume and decrease the treatment time of MRgFUS. In the early treatments, the sonications were delivered at one or a small number of treatment depths in a grid pattern.\textsuperscript{86} The tissue was allowed to cool back to baseline before a subsequent sonication was performed, in order to avoid accumulation of heating in the near field due to overlap of the US beam. This need to take time for cooling limited the time available for treatment, and thus reduced overall efficacy. Optimization of placement of focal spots to avoid accumulated heating in the near field has greatly improved the treatment time. The systems have also evolved so that larger areas can be ablated during each sonication by electronically steering the US beam over a larger area. The ExAblate system steers the focal beam laterally to increase the width of the focal area, and when in "elongated" mode it steers the focal beam from a deeper to a more shallow location over the course of the sonication. For large fibroids, this steering in the depth direction can cover several centimeters in one sonication. Improved robotics and the ability to disable portions of the array that place unwanted tissue in the US-beam path have also been developed with the aim of increasing the patient population that are candidates for MRgFUS.

The Sonalleve system uses volumetric heating with real-time feedback. This sonication approach is based on the work of Salomir et al and Mougnot et al\textsuperscript{109,110} and utilizes heat diffusion by electrically steering the focal point in a predetermined circular path in the focal plane. Over time, the center of the “treatment cell” is filled in via thermal conduction and perfusion. To control the temperature increase
in each sonication location, the Sonalleve system uses the feature “real-time thermometry feedback”, by which it can automatically modify the sonication parameters to generate a spatially controlled temperature profile at the target location. The combination of the volumetric ablation and the real-time multislice temperature monitoring provides well-controlled maximum lesion temperature, predictable lesion volumes, and faster ablation of larger fibroids.111

**Cost-effectiveness**

As discussed, studies have concluded that MRgFUS is safe and effective in shrinking fibroids and producing symptom relief. It is a short outpatient procedure, and there are few adverse events or minor complications associated with it. However, according to the Blue Cross and Blue Shield technology assessment of MRgFUS for treatment of uterine fibroids,112 MRgFUS is still considered investigational, without sufficient proof that it “improves the net health outcome for any clinical application”, and currently not all insurance companies cover MRgFUS for uterine fibroid treatment. To address this assessment, there have been a number of cost-effectiveness analyses performed that have compared MRgFUS with conventional treatments for fibroids.113–115

O’Sullivan et al found MRgFUS to be in the range of currently accepted criteria for cost-effectiveness, along with hysterectomy and UAE, while Zowall et al found that a treatment strategy for symptomatic uterine fibroids starting with MRgFUS is likely to be cost-effective.113,114 Our group found that MRgFUS, as the first-line treatment for symptomatic fibroids, is preferred over both UAE and hysterectomy from a cost-effectiveness standpoint.115 Fennessy et al applied specific short-term quality-of-life decreases (“disutilities”) related to MRgFUS, UAE, and hysterectomy, for the cost-effectiveness analyses.116 This approach strengthened our results, as we took into account the difference in the quality of life and duration of recovery following each specific treatment procedure for uterine fibroids.

**Conclusion**

To determine the value and effectiveness of MRgFUS in the widely available therapeutic options for uterine fibroids, one can consider the feasibility studies that have proven the safety and efficacy of MRgFUS (which eventually led the FDA approval of this technology), together with multicenter clinical trial results that showed the treatment’s efficacy in symptom reduction and resolution with the low occurrence rate of side or adverse effects. As the technology advances and improves, and the operators become more aware of how to circumvent anatomical obstacles, such as bowel and scar tissue, MRgFUS treatment time is decreasing and more patients become treatment-eligible. Recent studies have indicated that MRgFUS is a safe and effective treatment option in AA women, in whom this disease is more common and more symptomatic. Preliminary evidence would suggest that MRgFUS is not a definitive roadblock to future pregnancies, although this is an area that will require more exploration for confirmation. Furthermore, cost-effectiveness studies have concluded that MRgFUS is cost-effective as a uterine-sparing, noninvasive therapy for eligible patients. As MRgFUS continues to mature and undergo technical improvements, we believe that it will be a first-choice therapy for many women and an important tool in the personalized therapy arsenal for uterine fibroids.

**Acknowledgments**

We acknowledge the pioneering image-guided therapy work of Dr Ferenc A Jolesz, MD, who passed away on December 31, 2014. He was instrumental in the concept and introduction of MRgFUS, and is missed by his friends, colleagues, and mentees. This study was supported by grant R25 CA089017-06A2.

**Disclosure**

FMF, CMT, and NJM have received support at different times over the past 13 years from InSightec Inc for the performance of uterine fibroid clinical trials at Brigham and Women’s Hospital, as part of multicenter clinical trials. The other authors report no conflicts of interest in this work.

**References**


78. Zhao WP, Chen JY, Chen WZ. Effect of biological characteristics of different types of uterine fibroids, as assessed with T2-weighted magnetic resonance imaging, on ultrasound-guided high-intensity focused ultrasound ablation. Ultrasound Med Biol. 2015;41(2):423–431.


Fischer et al


